- Trials with a EudraCT protocol (75)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
75 result(s) found for: Medical Device Reporting.
Displaying page 1 of 4.
EudraCT Number: 2012-000867-25 | Sponsor Protocol Number: OMS302-ILR-004 | Start Date*: 2012-07-23 | |||||||||||
Sponsor Name:Omeros Corporation | |||||||||||||
Full Title: A Phase 3 Randomised, Double-Masked, Placebo-Controlled Study of the Pharmacokinetics of OMS302 and the Effect of OMS302 on Intraoperative Pupil Diameter and Early Postoperative Pain in Subjects Un... | |||||||||||||
Medical condition: Intraocular Lens Replacement with Pharmacoemulsification | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003997-33 | Sponsor Protocol Number: NOAH-AFNET6 | Start Date*: 2016-11-18 | |||||||||||
Sponsor Name:Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork] | |||||||||||||
Full Title: Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes | |||||||||||||
Medical condition: Atrial fibrillation (AF) is one cause of stroke. Stroke rate is increased in patients with atrial high rate episodes (AHRE, an early stage of AF) as well, even if stroke rates are lower when compa... | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) BG (Completed) SE (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) PT (Prematurely Ended) GR (Completed) DK (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004971-30 | Sponsor Protocol Number: FLUGEN-H3N2-V002 | Start Date*: 2018-04-27 | |||||||||||
Sponsor Name:FluGen, Inc | |||||||||||||
Full Title: A Phase 2a Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Bris10 M2SR (H3N2 A/Brisbane/10/2007) Vaccine Administered as a Single Intranas... | |||||||||||||
Medical condition: Prophylactic H3N2(A/Brisbane/10/2007) monovalent influenza vaccine, Bris10 M2SR, for protection against influenza disease caused by seasonal influenza A viruses. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023873-20 | Sponsor Protocol Number: B1971009(6108A1-3001) | Start Date*: 2011-11-08 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE LOT CONSISTENCY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MENINGOCOCCAL SEROGROUP B BIVALENT RLP2086 VACCINE IN H... | |||||||||||||
Medical condition: BACTERIAL MENINGITIS. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) FI (Completed) CZ (Completed) GB (Completed) ES (Completed) PL (Completed) IT (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000173-29 | Sponsor Protocol Number: N01237 | Start Date*: 2006-04-13 | |||||||||||
Sponsor Name:UCB S.A. (Global Medical Affairs) | |||||||||||||
Full Title: A multicenter, open-label single-arm follow-up trial evaluating the long-term safety of levetiracetam, for patients suffering from epilepsy and coming from the study N01175. | |||||||||||||
Medical condition: Epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003693-31 | Sponsor Protocol Number: C3671013 | Start Date*: 2021-09-30 | |||||||||||
Sponsor Name:Pfizer Inc., 66 Hudson Boulevard East New York, NY 10001 | |||||||||||||
Full Title: A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS | |||||||||||||
Medical condition: Prevention of RSV-associated lower respiratory tract illness in adults 60 years of age and older by active immunization | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001259-29 | Sponsor Protocol Number: UoL001306 | Start Date*: 2019-03-12 | |||||||||||
Sponsor Name:University of LIverpool | |||||||||||||
Full Title: A PHASE 1B/2A STUDY TO ASSESS THE TOLERABILITY AND ADVERSE EFFECT PROFILE OF CYSTEAMINE (CYSTAGON) IN ADULTS AND CHILDREN WITH HOMOZYGOUS ΔF508 CYSTIC FIBROSIS, IN PATIENTS TAKING EPIGALLOCATECHIN-... | |||||||||||||
Medical condition: DeltaF508 Homozygous Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002780-42 | Sponsor Protocol Number: TR701-111 | Start Date*: 2015-06-29 | |||||||||||
Sponsor Name:Trius Therapeutics [...] | |||||||||||||
Full Title: A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Ad... | |||||||||||||
Medical condition: Acute bacterial skin and skin structure infections | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000013-20 | Sponsor Protocol Number: 2018-000013-20 | Start Date*: 2018-05-07 |
Sponsor Name:KU Leuven | ||
Full Title: Placebo-controlled crossover study of the ability of Naloxegol to reverse opioid effect on colonic motor patterns in healthy volunteers | ||
Medical condition: This study will be performed in healthy volunteers. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000091-14 | Sponsor Protocol Number: FFR102123 | Start Date*: 2004-09-17 |
Sponsor Name:GlaxoSmithKline, S.A | ||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg ... | ||
Medical condition: Perennial allergic rhinitis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) SE (Completed) LV (Completed) LT (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-003475-13 | Sponsor Protocol Number: A1281148 | Start Date*: 2006-12-08 | |||||||||||
Sponsor Name:Pfizer Pharma GmbH | |||||||||||||
Full Title: A SIXTEEN-WEEK, MULTI-CENTER, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF SWITCHING FROM QUETIAPINE TO ZIPRASIDONE IN SUBJECTS DIAGNOSED WITH SCHIZOPHRENIA OR SCHIZOAFFECT... | |||||||||||||
Medical condition: Schizophrenia and Schizoaffective Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004564-38 | Sponsor Protocol Number: KFL3501 | Start Date*: 2015-05-27 | |||||||||||||||||||||
Sponsor Name:Mundipharma Research Limited | |||||||||||||||||||||||
Full Title: A randomised, open label, two-period, cross-over, multi-centre study to compare correct inhaler handling of fluticasone/ formoterol breath-actuated inhaler (K-haler®) with that of Symbicort® Turboh... | |||||||||||||||||||||||
Medical condition: Asthma, Asthma-COPD Overlap Syndrome (ACOS) and Chronic Obstructive Pulmonary Disease. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001673-75 | Sponsor Protocol Number: ABX464-401 | Start Date*: 2020-05-06 |
Sponsor Name:ABIVAX | ||
Full Title: A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failu... | ||
Medical condition: COVID-19 infection (infection with SARS-CoV-2 virus) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2022-001795-34 | Sponsor Protocol Number: CL-N-HTX-Paed-II/10/20 | Start Date*: 2023-01-30 | |||||||||||
Sponsor Name:Dr. Franz Köhler Chemie GmbH | |||||||||||||
Full Title: A prospective randomized single blind multicenter phase II study of organ perfusion with Custodiol-N compared with Custodiol in heart transplantation in children | |||||||||||||
Medical condition: Preservation of hearts prior to heart transplantation in children | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000369-37 | Sponsor Protocol Number: NKT102245 | Start Date*: 2005-02-01 |
Sponsor Name:GlaxoSmithKline Group of Companies | ||
Full Title: A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjun... | ||
Medical condition: Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: HU (Completed) GB (Completed) ES (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017838-44 | Sponsor Protocol Number: CJO-201 | Start Date*: 2010-04-21 | |||||||||||
Sponsor Name:Sequel Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Pilot Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Safety, Tolerability and Preliminary Efficacy Study of K201 Oral for the Prevention of Atrial Fibrillation (AF) Recurre... | |||||||||||||
Medical condition: Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005926-22 | Sponsor Protocol Number: FLT3501 | Start Date*: 2007-03-14 | |||||||||||
Sponsor Name:Mundipharma Research Ltd. | |||||||||||||
Full Title: An open, randomised, parallel group, multicentre study to compare the efficacy and safety of FlutiForm pMDI vs Seretide pMDI in adult subjects with mild to moderate-severe persistent, reversible as... | |||||||||||||
Medical condition: Asthma bronchial | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000499-25 | Sponsor Protocol Number: 28733 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Merck Serono International S.A. | |||||||||||||
Full Title: International, multicenter, single-arm, open-label, 12-week phase IIIb study to evaluate RebiSmartTM suitability for self-injection of Rebif New Formulation (RNF) in multidose cartridges in patien... | |||||||||||||
Medical condition: Relapsing forms of Multiple Sclerosis (RMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003663-35 | Sponsor Protocol Number: PBF-680CT-05 | Start Date*: 2018-06-13 | |||||||||||
Sponsor Name:Palobiofarma S.L | |||||||||||||
Full Title: A phase II, double-blind, randomized, parallel-group, placebocontrolled multi-center study to investigate the effect of the adenosine A1 receptor antagonist PBF-680 on forced expiratory volume in 1... | |||||||||||||
Medical condition: patients with mild-to-moderate persistent atopic asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001561-32 | Sponsor Protocol Number: 201900237 | Start Date*: 2020-04-28 | ||||||||||||||||
Sponsor Name:University Medical Center Groningen | ||||||||||||||||||
Full Title: Dupilumab in adults with severe chronic hand eczema with an inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled proof of concept efficacy study | ||||||||||||||||||
Medical condition: Hand eczema | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
